THYQUIDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION 100 MCG/5ML
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 May 2023)
What this means for you
This application is over — abandoned 08 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90350942
- Mark type
- Design + words
- Filed
- 01 Dec 2020
- Published for opposition
- 08 Feb 2022
- Abandoned
- 08 May 2023
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of hypothyroidism, thyroid hormone deficiency, myxedema and thyroid tumors
Owner
- AZURITY PHARMACEUTICALS, INC., WOBURN, MA, US
- VistaPharm, Inc., New Providence, NJ, US
- VistaPharm, Inc., New Providence, NJ, US
Prosecution history
- 08 May 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 08 May 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 19 Oct 2022 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 06 Oct 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Oct 2022 — SOU EXTENSION 1 GRANTED
- 04 Oct 2022 — SOU EXTENSION 1 FILED
- 04 Oct 2022 — SOU TEAS EXTENSION RECEIVED
- 03 Aug 2022 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 05 Apr 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Feb 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Feb 2022 — PUBLISHED FOR OPPOSITION
- 19 Jan 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Jan 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Jan 2022 — EXAMINER'S AMENDMENT ENTERED
- 06 Jan 2022 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED